A Phase 2, Double Blind, Placebo Controlled Study of RSLV-132 in Subjects with Primary Sjogren's Syndrome

Trial Profile

A Phase 2, Double Blind, Placebo Controlled Study of RSLV-132 in Subjects with Primary Sjogren's Syndrome

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Aug 2018

At a glance

  • Drugs RSLV 132 (Primary)
  • Indications Sjogren's syndrome
  • Focus Pharmacodynamics
  • Acronyms RSLV-132
  • Sponsors Resolve Therapeutics
  • Most Recent Events

    • 09 Aug 2018 Status changed from active, no longer recruiting to completed.
    • 01 Jun 2018 Planned End Date changed from 15 Jan 2018 to 15 Jan 2019.
    • 01 Jun 2018 Planned primary completion date changed from 15 Nov 2017 to 15 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top